Oncomed pharmaceuticals inc (OMED)
Income statement / TTM
Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12
Revenue:
Revenue

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

38,563

-

-

-

21,231

-

22,130

21,538

20,877

25,216

27,575

41,903

43,231

39,559

51,507

44,931

41,355

37,779

19,567

9,128

0

0

0

Other revenue

-

-

-

-

-

-

-

3,785

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,972

11,972

0

0

0

Total revenue

-

-

40,465

39,790

-

-

24,546

25,016

-

25,772

24,540

22,562

25,899

0

0

0

-

-

-

-

37,779

26,539

21,100

0

0

0

Operating expenses:
Research and development

34,443

35,037

37,203

44,239

59,839

75,514

90,684

105,302

109,713

112,150

109,501

101,838

92,873

86,744

83,032

79,154

76,430

72,747

64,873

57,181

50,048

42,673

39,116

0

0

0

General and administrative

18,172

16,609

16,778

17,171

16,761

17,314

17,936

18,612

18,827

19,441

19,484

18,988

18,583

17,192

16,171

15,334

13,753

14,686

14,346

12,858

11,630

9,027

7,568

0

0

0

Restructuring charges

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

54,466

51,661

54,065

63,937

79,127

95,340

111,063

123,914

128,540

131,591

128,985

120,826

111,456

103,936

99,203

94,488

90,183

87,433

79,219

70,039

61,678

51,700

46,684

0

0

0

Loss from operations

-10,045

3,216

-13,600

-24,147

-40,973

-71,607

-86,517

-98,898

-103,387

-105,819

-104,445

-98,264

-85,557

-76,361

-57,300

-51,257

-50,624

-37,405

-35,274

-29,177

-23,899

-25,161

-25,584

0

0

0

Interest and other income, net

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Interest and other income, net

-

-

1,347

1,037

-

-

501

416

-

273

287

185

170

155

110

89

105

100

-66

-221

-228

0

0

0

-

-

Loss before income taxes

-8,483

4,550

-12,253

-23,110

-40,145

-70,849

-86,016

-98,482

-103,088

-105,546

-104,158

-98,079

-85,387

-66,044

0

0

-

0

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss before provision for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

-

-

-

-

Income tax provision (benefit)

-382

-1,478

-1,474

-1,082

-1,083

10

15

15

14

1

4

12

20

-522

-499

-500

-509

48

0

0

-

0

-

-

-

-

Interest and other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Net loss

-8,101

6,028

-10,779

-22,028

-39,062

-70,859

-86,031

-98,497

-103,102

-105,547

-104,162

-98,091

-85,407

-75,684

-56,691

-50,668

-50,010

-39,297

-37,297

-31,344

-26,071

-25,383

-25,656

0

0

0

Net loss per common share, basic and diluted

-0.12

0.16

-0.10

-0.15

0.25

-0.28

-0.40

-0.61

-0.56

-0.77

-0.91

-0.90

-0.82

-0.81

-0.72

-0.49

-0.51

-0.18

-0.53

-0.47

14.97

-0.15

-8.83

-7.92

-3.45

-3.64

Shares used to compute net income (loss) per common share, basic

-

38,508

-

-

-

37,662

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used to compute net income (loss) per common share, diluted

-

38,512

-

-

-

37,662

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used to compute net loss per common share, basic and diluted

-

-

38,389

38,243

-

-

37,623

37,271

37,157

33,758

30,300

30,221

30,111

30,072

30,022

29,908

29,839

29,773

29,601

29,443

28,765

23,178

1,091

1,084

1,060

1,032